M

Medline

Makes and delivers medical supplies to hospitals

Bilingual Product Support Specialist - Non-Acute

Full-Time
$54k - $81k/yr+ Bonus and/or incentive
Junior
Bachelor's
Houston, TX, USA
In Person
Solution EngineeringPre-Sales Solution Engineering, Implementation & Technical Account Management

About the job

Requirements
  • A bachelor's degree is required.
  • At least 1 year of sales or related experience is required.
  • Fluency in written and conversational Spanish is required.
  • Experience developing presentations for various audience levels is required.
  • Willingness to travel up to 100% of the time for business purposes, both within and outside the state, is required.
Responsibilities
  • Support corporate sales initiatives to grow market share through clinical, sales, and product consulting activities.
  • Coordinate product and/or program conversions to improve customer experience and support system implementation.
  • Assist in preparing technical proposals for Clinical Services products and programs that address customer needs and explain integration and implementation within customer facilities.
  • Prepare and present customer needs plans to Medline sales teams, ensuring each plan is feasible within cost, time, and environmental constraints.
  • Research and analyze customer backgrounds, product needs, and key objectives, and communicate relevant information proactively to the sales force.
  • Gather customer data and participate in developing presentations that keep customers current on products, product enhancements, and product conversions.
  • Collaborate with Clinical Services and Sales teams on product conversions, trials, and market research.
  • Provide Sales teams with Clinical Services technical and sales presentation support to help secure new business, integrate customers successfully, and increase utilization of established products.
  • Support sales representatives through pre-sales and/or post-sales technical support.
  • Assist the Clinical Resources Manager with training, development, and delivery of Clinical Services products and programs.

About the company

M

Medline

View
Website

Medline makes and distributes medical and surgical supplies for hospitals, surgery centers, nursing homes, physician offices and other care sites. It runs its own factories alongside a large network of warehouses and delivery routes, so one company can produce exam gloves, gowns and surgical kits and then deliver them straight to the bedside. Many health systems sign multi-year prime vendor agreements that make Medline the source for most of their medical-surgical supplies. It earns money selling its own products and those of other manufacturers, together with supply chain services. Medline was founded in 1966 and is based in Northfield, Illinois.

Company Size

10,001+

Company Stage

IPO

Headquarters

Northfield, Illinois

Founded

1966

Get referred to Medline

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sales keep climbing: net sales rose 11.6% to $7.7 billion in the April to June 2026 quarter.
  • Medline pays for school: full-time staff get 80% of tuition reimbursed, starting 30 days after hire for undergraduate study.
  • A deep network absorbs shocks: losing its Tracy, California warehouse in June 2026 cut only about 4% of US space.

What critics are saying

  • Quality lapses hit stock grants: shares fell 7% after a May 2026 FDA warning over contamination at a Medline plant.
  • Tariffs squeeze profit: second-quarter 2026 net income fell 58% to $139 million as tariffs raised product costs.
  • Buyout firms still hold sway: Blackstone, Carlyle and Hellman & Friedman each kept about 18% of Medline after listing.

What makes Medline unique

  • Medline sells mostly its own goods: its Medline Brand products made 47.1% of net sales in early 2026.
  • Medline drives its own deliveries: a fleet of over 2,100 MedTrans trucks reaches 95% of its US operations next day.
  • The founding family keeps a voice: the Mills family held 17.8% of voting power after Medline listed.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Investing.com
Oct 17th, 2026
GIC Private Ltd sells $274.8 million in Medline (MDLN) shares.

GIC Private Ltd sells $274.8 million in Medline (MDLN) shares. Published Oct 17, 2026, 11:16 AM (C) Reuters GIC Private Ltd, a significant shareholder and director of Medline Inc. (NASDAQ:MDLN), reported the sale of a substantial block of shares. The Singapore-based entity disposed of 7,816,987 shares of Medline Class A Common Stock on October 8, 2026, at a price of $35.15 per share. The transaction amounted to a total value of $274,767,093. The sale comes as Medline shares have declined 24.5% over the past six months, currently trading at $35.96 with a market capitalization of $48.08 billion. According to InvestingPro analysis, the stock appears undervalued at current levels, with the platform identifying Medline as a prominent player in the Healthcare Equipment & Supplies industry. The company generates $29.94 billion in revenue with 12% growth. Investors can access detailed valuation metrics and 5 additional ProTips through comprehensive Pro Research Reports available for Medline and 1,400+ other US equities. Following this transaction, GIC Private Ltd directly holds 16,453,806 shares of Medline Class A Common Stock. Additionally, 69,408,506 shares are beneficially owned indirectly through Hux Investment Pte. Ltd. GIC Private Ltd, identified as a 10% owner of Medline, disclaims beneficial ownership of the securities except to the extent of its pecuniary interest. The indirectly held shares are owned directly by Hux Investment Pte. Ltd., which shares the power to vote and dispose of these securities with GIC Special Investments Pte. Ltd. and GIC Private Ltd. GIC Special Investments Pte. Ltd. is wholly owned by GIC Private Ltd and is its private equity investment arm. GIC Private Ltd, in turn, is wholly owned by the Government of Singapore, which manages Singapore's foreign reserves and disclaims beneficial ownership of these securities. -0.61 (-1.67%) Closed · 16/10 · USD -0.95 (-2.64%) After Hours · 16:51:49 Start trading MDLN now The filing was dated October 13, 2026. In other recent news, Medline Industries reported second-quarter 2026 revenue of $7.7 billion, marking a 12% increase from the previous year. The company's adjusted earnings were $0.50 per share, with organic growth reaching about 13% when excluding tariff refunds. Despite these positive figures, investors expressed concern over a lower full-year profit outlook and rising costs. In analyst updates, BTIG reiterated a Buy rating for Medline with a $55 price target following a tour of the company's Illinois distribution center. Meanwhile, Tigress Financial Partners lowered its price target for Medline to $55 from $62, maintaining a Buy rating. Tigress Financial highlighted the company's AI-enabled supply-chain transformation as a factor supporting durable growth. They also noted that recent fire-related issues could present a buying opportunity. These developments provide a comprehensive view of Medline's current financial and operational landscape. Should you invest $2,000 in MDLN right now? ProPicks AI evaluates MDLN alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias - it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if MDLN is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?

MarketScreener
Oct 13th, 2026
Medline: South Carolina Pediatric Alliance selects Medline as Prime Vendor.

Medline: South Carolina Pediatric Alliance selects Medline as Prime Vendor. Published on 10/13/2026 at 10:43 am EDT South Carolina Pediatric Alliance selects Medline as Prime Vendor Agreement provides access to Medline's medical-surgical products and supply chain solutions to support operational performance By Medline Newsroom Staff | October 12, 2026 Northfield, Ill., Oct. 12, 2026 - Medline (Nasdaq: MDLN) today announced it signed a new Prime Vendor agreement with South Carolina Pediatric Alliance (SCPA). Formed through the partnership of Palmetto Pediatrics and Sandhills Pediatrics, two longstanding pediatric practices serving families in the Midlands of South Carolina, SCPA today provides comprehensive pediatric care through 10 locations across the Midlands, with expanded access to care through evening and weekend services. SCPA remains committed to providing high-quality, compassionate care to children and families while continuing to grow alongside the communities it serves. "Having a dependable supply partner is essential to supporting our physicians and clinical teams across every SCPA location," said Caroline Currin, chief operating officer of South Carolina Pediatric Alliance. "This partnership with Medline will help us create greater consistency across our network, strengthen our day-to-day operations and ensure our teams have the quality supplies they need to provide exceptional care to our patients." Through this agreement, SCPA will have access to Medline's comprehensive brand portfolio of quality medical-surgical products and powerful distribution capabilities to help streamline ordering and timely, reliable delivery of medical supplies. SCPA also will use Medline's supply chain expertise to help optimize clinic setup, complete PAR-level analysis and increase visibility into its supply chain to make informed operational decisions across the network. "As we continue to grow, it is important that we look at every opportunity to operate more efficiently and ensure our resources are being used where they have the greatest impact," said Steve Hatchell, chief financial officer of South Carolina Pediatric Alliance. "Medline stood out as a partner that could help us achieve meaningful savings while maintaining the quality of supplies our teams rely on every day. Those efficiencies ultimately allow us to keep our focus where it belongs, on providing exceptional care to the children and families we serve." Brad Miriam, executive vice president of non-acute sales at Medline, said, "We look forward to partnering with South Carolina Pediatric Alliance as they continue to grow and serve communities across South Carolina. We are proud to support them in strengthening their operations and supply management so that they can continue to provide great care for their patients and families." About Medline Medline is the largest provider of medical-surgical products and supply chain solutions serving all points of care. Through its broad product portfolio, resilient supply chain and leading clinical solutions, Medline helps healthcare providers improve their clinical, financial and operational outcomes. Headquartered in Northfield, Ill., the company employs more than 45,000 people worldwide and operates in more than 100 countries. To learn more about how Medline makes healthcare run better, visit www.medline.com. Attachments * Original document * Permalink Disclaimer Medline Inc. published this content on October 12, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 13, 2026 at 14:42 UTC. (C) Publicnow - 2026

PR Newswire
Oct 12th, 2026
Medline launches enhanced TrackPoint(TM) to simplify inventory management for post-acute care.

Medline launches enhanced TrackPoint(TM) to simplify inventory management for post-acute care. Oct 12, 2026, 16:25 ET Combines real-time inventory tracking with PointClickCare(R) integration to reduce manual work and improve supply visibility NORTHFIELD, Ill., Oct. 12, 2026 /PRNewswire/ - Medline (Nasdaq: MDLN) today announced the launch of an enhanced version of TrackPoint(TM), its online inventory management and patient item usage solution designed to help long-term care and inpatient hospice providers more easily track supplies from Medline, capture patient-level usage and gain visibility into inventory across locations. TrackPoint provides an easy-to-use solution that helps facilities streamline how they order and manage supplies purchased from Medline. The platform gives providers greater control over supply management by automating manual workflows and enabling more accurate tracking of what is on hand, where products are used and when replenishment is needed. "We know that our customers, especially in post-acute care, often don't have access to inventory management solutions and charge-capturing systems purpose-built for them," said Dave Kordik, vice president customer technology solutions, Medline. "Everything is very manual. We saw an opportunity to provide a more streamlined, modernized application for them." TrackPoint integrates with PointClickCare(R) for real-time patient data synching and helps providers improve inventory efficiency through several core capabilities: * Real-time Medline inventory visibility to understand what is on hand, where it is located, and what needs to be restocked. * Patient item and service usage tracking to support more accurate documentation and data needed for proactive care and operational efficiency. * Standardized workflows to create consistent processes for receiving, dispensing and tracking supplies and services. * Reduced manual work and errors through digital processes and barcode scanning. * Simplified purchasing through Medline.com to streamline ordering and reduce duplicate data entry. * Accurate multi-location inventory to manage multiple facilities for better counts and replenishment to align supply spend with patient needs and services delivered. "Our goal is to make inventory management easier and more actionable for long-term care and inpatient hospice providers," said Renee Fisher, senior vice president, national field sales, post-acute care, Medline. "We're excited to help customers improve visibility into supply usage, streamline everyday workflows and make more informed decisions that support both operational efficiency and patient care." About Medline Medline is the largest provider of medical-surgical products and supply chain solutions serving all points of care. Through its broad product portfolio, resilient supply chain and leading clinical solutions, Medline helps healthcare providers improve their clinical, financial and operational outcomes. Headquartered in Northfield, Illinois, the company employs more than 45,000 people worldwide and operates in more than 100 countries. To learn more about how Medline makes healthcare run better, visit www.medline.com. SOURCE Medline

Business Wire
Oct 6th, 2026
UNIQURE N.V. QURE INVESTORS: contact Kirby McInerney LLP about the firm's securities investigation following 37.3% share drop.

UNIQURE N.V. QURE INVESTORS: contact Kirby McInerney LLP about the firm's securities investigation following 37.3% share drop. NEW YORK-(BUSINESS WIRE)-The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices. What Happened? On September 29, 2026, uniQure released 48-month data for ongoing Phase I/II studies of AMT-130, the Company's lead pipeline candidate to treat Huntington's disease. The 48-month data revealed a smaller treatment benefit than the one the Company reported at 36 months. Specifically, AMT-130 showed a "44% slowing of disease progression" at 48 months under the composite Uniform Huntington's Disease Rating Scale, compared to a 75% disease slowing at 36 months. In June, uniQure had announced that the Company intended to submit an application to the FDA to bring AMT-130 to the market and did so on September 2, 2026, submitting a Biologics License Application to the FDA based upon its 36-month data analysis. On the disclosure of the Company's 48-month AMT-130 results, the price of uniQure shares declined by $14.60 per share, or approximately 37.3%, from $39.11 per share on September 28, 2026 to close at $24.51 on September 29, 2026. What Should I Do? At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws. If you purchased or otherwise acquired uniQure securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost. Kirby McInerney LLP is a New York-based plaintiffs' law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm's efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found on Kirby McInerney LLP's website. More News From Kirby McInerney LLP NEW YORK-( BUSINESS WIRE )-The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE FIRM'S INVESTIGATION]What Happened?On June 2, 2026, the FDA published a warning letter that detailed Medline's "significant violations of Curr... NEW YORK-( BUSINESS WIRE )-The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Alphabet Inc. ("Alphabet" or the "Company") (NASDAQ: GOOGL; GOOG) securities between May 19, 2026 and July 16, 2026, inclusive ("the Class Period"). If you suffered a loss on your Alphabet investments, you have until December 1, 2026 to request lead plaintiff appointment.[CONTACT THE FIRM IF YOU SUFFERED A LOSS]Investors are encouraged to fill ou... NEW YORK-( BUSINESS WIRE )-The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Coastal Financial Corporation ("Coastal" or the "Company") (NASDAQ: CCB) securities between October 28, 2024 and July 29, 2026, inclusive ("the Class Period"). If you suffered a loss on your Coastal investments, you have until December 1, 2026 to request lead plaintiff appointment.[CONTACT THE FIRM IF YOU SUFFERED A LOSS]Investors are encouraged... Kirby McInerney LLP. NASDAQ:QURE Release Versions

GlobeNewswire
Oct 1st, 2026
Bragar Eagel & Squire, P.C. is investigating Medline Inc. on behalf of Medline stockholders and Encourages Investors to contact the firm.

Bragar Eagel & Squire, P.C. is investigating Medline Inc. on behalf of Medline stockholders and Encourages Investors to contact the firm. Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Medline (MDLN) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Medline and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at [email protected] or by telephone at (212) 355-4648. NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) - What's Happening: * Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN) on behalf of Medline stockholders. Our investigation concerns whether Medline has violated the federal securities laws and/or engaged in other unlawful business practices. Investigation Details: * On June 2, 2026, the FDA published a warning letter that detailed Medline's "significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals," including failing "to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications." On this news, the price of Medline shares declined by $2.56 per share, or approximately 7.2%, from $35.75 per share on to June 1, 2026 to close at $33.19 on June 2, 2026. * On August 5, 2026, Medline released its second quarter 2026 financial results and revealed during its earnings call that some of the remediation steps it has taken in response to the FDA's letter, such as taking products off the market, have "result[ed] in earnings loss." On this news, the price of Medline shares declined by $5.37 per share, or approximately 12.8%, from $42.04 per share on August 4, 2026 to close at $36.67 on August 5, 2026. Next Steps: * If you purchased or otherwise acquired Medline shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn. Contact Information: Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Melissa Fortunato, Esq. (212) 355-4648 [email protected] www.bespc.com